<DOC>
	<DOCNO>NCT00925873</DOCNO>
	<brief_summary>In study , patient randomly assign either receive fludarabine ( 20 mg/m2/d ) addition induction chemotherapy , consolidation chemotherapy 3 subsequent re-induction course maintenance .</brief_summary>
	<brief_title>GOELAMS SA4 Study : Role Fludarabine Treatment Acute Myeloid Leukemia Elderly</brief_title>
	<detailed_description>Eligibility enrollment study limit patient age 60 75 year old previously untreated de novo AML define morphologically French-American-British ( FAB ) classification exception M3 M7 subtypes.10,11 The bone marrow aspirate show least 30 percent nonerythroid blast cell . Patients eligible performance status diagnosis 2 accord World Health Organization ( WHO ) grade system , congestive heart failure abnormal leave ventricular ejection fraction , severe hepatic renal disturbance relate leukemia ( hepatic enzyme level four time normal value , serum bilirubin 35 micromol/L , creatinine 150 micromol/L ) . Patients previous unexplained cytopenia eligible study . Conversely , patient history document myelodysplastic myeloproliferative syndrome previously treat chemotherapy radiation could enter study . The study receive June 1996 approval ethic ' board Nancy Hospital write informed consent give eligible patient enter study , accordance Declaration Helsinki . The enrollment period open November 1996 April 2000 .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>patient age 60 75 year old untreated de novo AML performance status le 2 performance status 2 congestive heart failure abnormal leave ventricular ejection fraction severe hepatic renal disturbance history document myelodysplastic myeloproliferative syndrome patient previously treat chemotherapy radiation</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Fludarabine</keyword>
	<keyword>AML</keyword>
	<keyword>elderly patient</keyword>
</DOC>